- MediPharm Labs (LABS) has appointed Bryan Howcroft to lead MediPharm’s next phase of international growth as CEO
- Howcroft will apply his experience in registering, distributing, and selling medically registered products in the United States, European Union and other global markets
- Bryan’s tenure at Southmedic included an extremely significant scaling of the business to a multisite operation
- Bryan also has significant European experience as a healthcare IT executive in Belgium for over four years
- MediPharm Labs (LABS) is in the grey, trading at C$0.28 at 2:32 pm ET
MediPharm Labs (LABS) is pleased to announce that Bryan Howcroft will join MediPharm Labs as Chief Executive Officer and Director, effective November 15, 2021.
Bryan Howcroft brings over 20 years of leadership in multiple industries including medical devices, healthcare imaging, and manufacturing. Most recently, Bryan held the position of Chief Operational Officer and Chief Financial Officer of Southmedic, a company that provides healthcare products, custom manufacturing, and distribution in over 60 countries globally.
Bryan’s tenure at Southmedic included an extremely significant scaling of the business to a multisite operation. Southmedic is recognized as one of Canada’s largest privately held medical device companies.
Bryan also has significant European experience as a healthcare IT executive in Belgium for over four years. In 2021, MediPharm Labs’ main growth area has been in the European markets and under the leadership of Bryan Howcroft, it expects to accelerate the business opportunities in that region.
“As a pharmaceutical company specialized in precision-based cannabinoids, MediPharm Labs was seeking a CEO who could lead the charge on increased sales in the medical and consumer markets. We found that CEO in Bryan, who has the experience and expertise in growing medical industry business coupled with knowledge on effective operational management,” said Chris Taves, Chairman, MediPharm Labs.
“Bryan is a tenacious leader who believes in a customer-first approach that will be critical for MediPharm to scale our business, and will bring a healthy level of urgency to pursue the many opportunities that lie ahead,” continued Taves.
Bryan holds an MBA from Laurentian University, a Bachelor of Business Administration from Nipissing University, and is a Chartered Professional Accountant.
“I look forward to bringing to MediPharm my successful scaling revenue and business operations and to building long-term competitive advantage,” said Bryan Howcroft.
MediPharm looks forward to Bryan joining the team in November 2021 to plan for the strong execution of strategic priorities in 2022. These priorities are focused on increased sales, profitability and enhancing the company’s position as the go-to supplier of precision-based cannabinoids and finished products to the global pharmaceutical industry.
In connection with Bryan’s appointment as CEO, MediPharm granted 2,008,928 RSUs and 951,920 stock options to him with an exercise price set at the close of business on October 20, 2021.
Each option grant has a five-year term expiring October 20, 2026. The RSUs and options vest in five equal instalments, the first of which vests immediately with the four other instalments vesting on the dates which are six, twelve, eighteen and twenty-four months from the grant date.
Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms.
MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers.
MediPharm Labs (LABS) is in the grey, trading at C$0.28 at 2:32 pm ET.
